Market Newsdesk

LAKEWOOD, Colo., Dec. 3, 2020 /PRNewswire/ — Today, Natural Grocers™, America’s Nutrition Education Experts^SM, announced the fifth annual Top 10 Nutrition Trends¹ predictions, a composite of the most anticipated and unexpected health, nutrition, and food trends for the coming year.

Natural Grocers’ Nutrition Education team, made up of health and wellness experts ranging from Registered Dietitians to Certified Natural Foods Chefs, collaborated with the retailer’s buyers and analysts, studied consumer-shopping preferences, pored over the latest research, and scrutinized the impact COVID-19 has had on its communities in order to pinpoint their predictions.  

“Our trends this year are dramatically different than previous years’ in that they’re far less fleeting. COVID-19 is a pandemic that sits on top of another pandemic in the United States of malnutrition and poor long-term health,” remarked Shelby Miller, MS, Natural Grocers’ Manager of Scientific Affairs and Nutrition Education. “Hence, 2021 holds broader trends that focus on improving nutrition to support our own health, as well as the health of our communities and our environment.”

Natural Grocers’ Top 10 Nutrition Trends® for 2021, which include getting back to the basics, immune-boosting strategies, The Climatarian and customized fitness nutrition, also offer “try this trend” tips for those who want to lean in to these trends in the coming months and beyond.

NATURAL GROCERS’ TOP 10 NUTRITION TRENDS FOR 2021:

Download hi-res images of Natural Grocers Top 10 Nutrition Trends
 

1. 
Our Health Is D-pendent on Vitamin D
While there are many things in life outside of our control, knowing our vitamin D levels is a simple step we can all take to elevate our health and the health of our families—it is something you can own as a proactive tool to be rooted in health. This unique nutrient plays a critical role in whether or not your immune system functions sufficiently and responds as needed. It is essential for lung health, supporting positive moods, brain function, and cognition, a healthy weight, a healthy pregnancy, children’s health, healthy blood sugar levels, healthy blood pressure, bone health, and muscle tone. Between 40 and 80 percent of American adults are outright deficient in vitamin D, while approximately 90 percent have suboptimal levels. Achieving optimal levels (between 30 and 50 ng/mL) of vitamin D through supplementation is crucial to experiencing its full range of benefits. Because darker skin hampers the body’s ability to synthesize vitamin D from sunlight, supplementation is especially important for people of color. A national survey reported average serum vitamin D concentrations of 28.1 ng/mL, 21.6 ng/mL, and 16.9 ng/mL in Caucasian, Mexican American, and African American adults aged 20 years and older, respectively. Vitamin D is a nutrient all of us should be focused on, and we all need to know our levels, but this is especially important for those with darker complexions.

TRY THIS TREND: Talk to your doctor about vitamin D testing to know your levels and add a vitamin D supplement to your healthcare routine—supplementing is easy, affordable, and effective. Learn more about the many benefits of vitamin D.

2. 
Everyday Immune Support for the Long Haul
Rather than trying to boost immunity when we’ve already fallen victim to whatever bug is going around, we have recognized the importance of “armoring up” and supporting our immune system on a daily basis so it can function optimally over the long haul. Dietary supplements make daily, long-term immune support so easy, and are backed by a mountain of research validating their health benefits. Boosting immune competence comes from nutrients you’re likely already familiar with: vitamin C, vitamin D, and zinc are three basics that are easy, affordable, and effective.

TRY THIS TREND: Nutrients like vitamin C, vitamin D, and zinc have loads of research supporting their immune benefits and are high-reward options.

3. 
Better Blood Sugar Balance
A growing body of research is showing that SARS-CoV-2 utilizes sugar to reproduce and that individuals with type-2 diabetes are at a higher risk of hospitalization and complications from COVID-19. We know that supporting blood sugar balance is a key method to be rooted in health. And the good news? There are lots of ways to achieve healthy blood sugar balance.

Whatever your health goals are and wherever your starting line is, there are many options to support healthy blood sugar balance. Ideas include giving up sugar-sweetened beverages, eliminating added sugar by trying a seven-day, no-added-sugar detox, or even trying out the ketogenic (keto) diet. Adding supplements that support blood sugar balance to your routine can help too—for example, alpha lipoic acid (ALA) is well-known to support insulin sensitivity and glucose utilization. No matter which route is chosen, it’s certain that balancing blood sugar will result in better mood, more balanced energy levels, and overall long-term health.

TRY THIS TREND: An easy way to try this trend is with some simple snack swaps. Check out the Keto Cups by Eating Evolved with no added sugar. Our favorite are the almond butter cups. You’re welcome.

4. 
De-Stressing in a Healthy Way (Without the Alcohol and Comfort-Food Eating)
2020 was messy in so many ways, and sometimes overwhelmed us with stress, but it also highlighted the importance of compassion and empathy. Compassion and empathy are crucial for helping us de-stress, and de-stressing is crucial for health. De-stressing is also remarkably beneficial for our immune health, as stress hormones like cortisol significantly impair our immune response. So, not only is de-stressing by offering compassion and empathy good for others, it’s also good for us, and in a meaningful way. 

We can all de-stress in a healthy way in two simple steps: Step one is to give our bodies the nutrients to support their ability to better cope with stress. These include magnesium, EPA and DHA from fish oil, B vitamins, vitamin C, phosphatidylserine (PS), curcumin, and adaptogenic herbs like rhodiola. Step two is to practice compassion and empathy. There are numerous benefits to practicing compassion and empathy, especially during a global pandemic. In addition to helping us connect with others, being empathetic also helps us regulate our emotions in times of stress. You can build empathy by engaging meaningfully with others, being aware of other people’s needs, and being kind to others and yourself.

TRY THIS TREND: Call a loved one, wear a mask if you can, give a stranger a genuine compliment. It’s important to practice compassion and empathy this year, not only for others, but for yourself as well.

5. 
Olive Oil Makes a Comeback
While coconut oil has had a well-deserved reign in the spotlight, 2021 will see olive oil making a comeback. Olive oil has always had a place in the “good fat” category, and for worthy reasons. This long-beloved oil has a well-known role in the health benefits of the Mediterranean diet—its noteworthy phenols and polyphenols contribute to its many nutrition superpowers, including its well-documented, anti-inflammatory activities.

TRY THIS TREND: Need proof of this as a trend in 2021? Look no further than the snack aisles where you’ll see olive oil chips, popcorn, and seaweed snacks.

6. 
The Climatarian

Consumer research is showing that while personal health is still a major driver for buying organic, consumers are shifting to buying organic for environmental reasons. This has led to the coining of the term “climatarian,” an individual who is making food choices with the intention of changing how our food is grown—shifting from a chemical-intensive model to one that promotes soil health, biodiversity, and healthy ecosystems—an important way to address climate change.  

TRY THIS TREND: The best way to align with this trend is to increase the amount of organic fruits and veggies in your diet. Fresh, canned, or frozen, any purchase of organic fruits and veggies is a vote for better human health, better soil health, better community health, and inevitably, better health for Mother Earth. Prioritizing regenerative/pasture-based meat and dairy products is another crucial method to make a significant difference in climate change.

7. 
Affordable, Healthy Meals at Home
Most of us have been cooking at home more since the start of the coronavirus outbreak, and while many of us had fun exploring complicated new recipes, and did so much baking in the beginning we had baked goods for days, as the months passed and we realized we’re in this for the long haul, priorities shifted and now we’re on the search for easy meals that taste good, and are also affordable and healthy. Consumers are looking for quick and affordable solutions to cooking, meal planning, and meals that do not require a lot of prep. 2021 will pave the way to reinventing what cooking at home looks like, and Natural Grocers is leading the way with its good4u℠ Meal Deals—dinner and lunch ideas, with some breakfast offerings coming soon, to feed your family affordably with healthy and delicious foods.

TRY THIS TREND: Check out one of the many Natural Grocers’ good4u Meal Deals for healthy, delicious, easy, and affordable options for you and your family.

8. 
Vegetables Will Be Front & Center
Over the years, nutrition advice has changed so much it’s led to more confusion than clarity about what and what not to eat, but one nutrition recommendation that has remained constant is that we all need to eat more vegetables. Produce in any form—canned, frozen, and fresh—provides what’s known as nutrient density. A nutrient dense food is something that packs loads of nutrition in the form of vitamins, minerals, and phytonutrients and plays a huge role in reducing our risk of chronic diseases. Veggies are some of the most nutrient dense foods out there, which is why they’ve remained a crucial part of diet recommendations, even amidst the whirlwind of changing nutrition advice. In 2021, as part of our effort to be rooted in health, we’ll make it a priority to try new veggies (ever tried leeks, heirloom tomatoes, or broccolini?), incorporate more produce-laden recipes into our repertoires, and discover new weekly staples that leave us feeling healthy and satisfied.

TRY THIS TREND: Check out naturalgrocers.com/recipes for veggie-centric recipe ideas. Print a produce calendar and aim to eat what’s in season.

9. 
Get Back to the Basics to Be Rooted in Health
SARS-CoV-2 is a virus that thrives on poor health, and it has forced us to recognize just how unhealthy we are as a country. As we move into 2021, we will be going back to the basics to take control of—and actively improve—our health. It’s time to finally prioritize sleep, clean up our diets, make time for exercise and daily movement, and recognize the value of key, foundational supplements. It almost seems too simple. Yet, there’s no denying that by prioritizing our own health, we also support the overall health of our communities.

TRY THIS TREND: Introduce yourself to the Foundational 5 Supplements or book a free, virtual coaching session with your local Nutritional Health Coach (NHC) to help you figure out the best first steps.

10. 
Customized Fitness Nutrition
With many people still avoiding gyms and group fitness studios, it’s given us the opportunity to not only perfect our at-home exercise routines, but to also optimize our workouts with real foods and targeted supplements. In 2021, we’ll see a decline in grab-and-go, post-workout foods and a rise in customized fitness nutrition and supplementation. Rather than grabbing a water and protein bar after our W.O.D. (work out of the day; don’t worry, we had to look it up too), in 2021 we will transition toward pairing whole, real foods with supplements that fuel movement and aid recovery. We will explore magnesium to support healthy muscle recovery, MCT oil to fuel more explosive workouts, collagen to support healthy joints and ligaments, beets and greens powders for healthy blood flow to muscles during our workouts, and a B-complex vitamin to keep us energized for our workouts.

TRY THIS TREND: Whether you prefer CrossFit, yoga, or something in between, try turmeric, a super nutrient that supports recovery, joint comfort, and immune health, or rhodiola, an adaptogenic herb that can increase energy and athletic performance, while reducing both mental and physical fatigue.

References available upon request.

About Natural Grocers by Vitamin Cottage
Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) is an expanding specialty retailer of natural and organic groceries, body care products and dietary supplements. The products sold by Natural Grocers must meet strict quality guidelines and may not contain artificial colors, flavors, preservatives or sweeteners, or partially hydrogenated or hydrogenated oils. The Company sells only USDA certified organic produce and exclusively pasture-raised, non-confinement dairy products, and free-range eggs. Natural Grocers’ flexible smaller-store format allows it to offer affordable prices in a shopper-friendly, safe and convenient retail environment. The Company also provides extensive free science-based nutrition education programs to help customers make informed health and nutrition choices. The Company, founded in 1955, has 160 stores in 20 states.

¹

 The statements in this press release have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure or prevent any disease.

View original content to download multimedia:http://www.prnewswire.com/news-releases/natural-grocers-predicts-top-10-nutrition-trends-for-2021-301185353.html

SOURCE Natural Grocers by Vitamin Cottage, Inc.

MIGDAL HAEMEK, Israel, Dec. 3, 2020 /PRNewswire/ — Camtek Ltd. (NASDAQ: CAMT) and (TASE: CAMT), today announced that company management is scheduled to participate in the 12th Annual CEO Summit, being held virtually this year on Wednesday, December 16, 2020.

The presentation material utilized during the CEO Summit will be made accessible on the investor page of the company’s website prior to the event.

The Virtual CEO Summit is by invitation only and is open to accredited investors and publishing research analysts.  Investors or analysts wishing to participate and meet virtually with Camtek’s management are welcome to contact the CEO Summit organizers or the investor relations team at Camtek.

About The 12^th Annual Virtual CEO Summit 2020

The CEO Summit is hosted by executive management from participating companies and will feature a virtual “round-robin” format consisting of small group meetings, each 40 minutes in duration. Each company will be available for up to six meeting slots during the conference, while investors and analysts will have the opportunity to meet with 12 of the participating management teams from 8:15a.m. until 5:15p.m. EST on December 16^th. In addition, each management team will present a pre-recorded company overview, which will be available to investors to view on the conference website approximately 24 hours in advance of the Summit.

The 16 management teams collectively hosting the 12^th Annual Virtual CEO Summit 2020 currently include:

ACM Research (ACMR), Advanced Energy Industries (AEIS), Aehr Test (AEHR), Alpha & Omega Semiconductor (AOSL), Axcelis (ACLS), Brooks Automation (BRKS), Camtek (CAMT), Cohu (COHU), Everspin Technologies (MRAM), FormFactor (FORM), Ichor Systems (ICHR), inTEST Corporation (INTT), Intevac (IVAC), Kulicke & Soffa (KLIC), Onto Innovation (ONTO) and Veeco Instruments (VECO).  Intro-act is sponsoring the conference.

The Virtual CEO Summit is by invitation only and is open to accredited investors and publishing research analysts.  As space is limited, please RSVP early.  Hosts reserve the right to limit attendance as necessary.  Advance registration and company meeting selection is required. Last day for registration is December 10, 2020. RSVP contacts are the CEO summit co-chairs, Laura J. Guerrant-Oiye ([email protected]) and Claire E. McAdams ([email protected]).

ABOUT CAMTEK LTD.

Camtek is a leading manufacturer of metrology and inspection equipment and a provider of software solutions serving the Advanced Packaging, Memory, CMOS Image Sensors, MEMS, RF and other segments in the mid end of the semiconductor industry.

Camtek provides dedicated solutions and crucial yield-enhancement data, enabling manufacturers to improve yield and drive down their production costs.

With eight offices around the world, Camtek has best-in-class sales and customer support organization, providing tailor-made solutions in line with customers’ requirements.

This press release is available at www.camtek.com  

This press release contains statements that may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations and assumptions of Camtek Ltd. (“we,” “us” and “our”). Forward-looking statements can be identified by the use of words including “believe,” “anticipate,” “should,” “intend,” “plan,” “will,” “may,” “expect,” “estimate,” “project,” “positioned,” “strategy,” and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Camtek to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including as a result of the effect of the COVID-19 crisis on the global markets and on the markets in which we operate, including the risk of the continuation of disruptions to our and our customers’, providers’, business partners and contractors’ businesses as a result of the COVID-19 pandemic; our dependency upon the semiconductor industry and the risk that unfavorable economic conditions or low capital expenditures may negatively impact our operating results; the highly competitive nature of the markets we serve, some of which have dominant market participants with greater resources than us; the rapid evolvement of technology in the markets in which we operate, and our ability to adequately predict these changes or keep pace with emerging industry standards; the risks relating to the concentration of a significant portion of our business in certain countries in the Asia Pacific Region, particularly China, Taiwan and Korea; changing industry and market trends; reduced demand for our products; the timely development of our new products and their adoption by the market; increased competition in the industry; price reductions; and those other factors discussed in our Annual Report on Form 20-F and other documents filed by the Company with the SEC as well as other documents that may be subsequently filed by Camtek from time to time with the SEC.

While we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. In addition, any forward-looking statements represent Camtek’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Camtek does not assume any obligation to update any forward-looking statements unless required by law.

View original content:http://www.prnewswire.com/news-releases/camtek-to-participate-in-the-virtual-12th-annual-ceo-investor-summit-2020-301185626.html

SOURCE Camtek Ltd

REDWOOD CITY, Calif., Dec. 3, 2020 /PRNewswire/ — Nevro Corp. (“Nevro”) (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, announced that Susan E. Siegel has been appointed as a member of the Board of Directors (the “Board”), effective December 2, 2020. Ms. Siegel succeeds Wilfred Jaeger, a founding investor in the company with nearly a decade of service to Nevro.

“On behalf of the entire Board, I thank Wilf for his many contributions to Nevro’s success,” said D. Keith Grossman, Chairman, President and CEO of Nevro. “Wilf’s visionary investment in the early days of Nevro was instrumental in developing a life-changing technology for tens of thousands of patients suffering from chronic pain. We wish Wilf the very best, and thank him for his influence and support over the years.”

“I would like to welcome Sue, who has over thirty years of experience in life sciences and healthcare, including advancing novel technologies and overseeing companies with high growth potential, to the Nevro Board,” Mr. Grossman said. “We look forward to Sue‘s contributions to our Board of Directors and the continuing success of Nevro.”

“I’m excited to be joining Nevro’s Board,” said Ms. Siegel. “I was attracted to the powerful combination of Nevro’s leading-edge technology, now being applied to important growth markets, and its stellar leadership team. Learning that Nevro’s products have been life changing for so many, with future untapped opportunities to profoundly impact people’s health, inspired me. I look forward to partnering with Keith, the Board, and the team to contribute to Nevro’s growth.”

Ms. Siegel has been at the forefront of disruptive technology and business model trends, encouraging companies large and small to adopt them for growth. Most recently, at General Electric, she held the positions of Chief Innovation Officer for GE and CEO of GE Ventures & Licensing from 2012-2019. Prior to joining GE, she led healthcare and life science investments as a General Partner at Mohr Davidow Ventures. Ms. Siegel also served as President and a member of the board of directors at Affymetrix Inc., leading the company’s transformation from an early-revenue startup to a global, multibillion-dollar market cap genomics leader. After transitioning to a corporate career from academic work in molecular biology and biochemistry, Ms. Siegel held executive leadership roles at Amersham, DuPont, and Bio-Rad. She currently serves on the boards of Illumina, Inc. and Align Technology, Inc.

About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro’s proprietary HF10® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

Investor Relations:

Julie Dewey

Vice President, Investor Relations and Corporate Communications
[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/nevro-announces-director-appointment-301185492.html

SOURCE Nevro Corp.

BETHESDA, Md., Dec. 3, 2020 /PRNewswire/ — Walker & Dunlop, Inc. announced today that it structured $14,120,000 in Fannie Mae financing for the acquisition of Blackbob Court Townhomes. Located in Olathe, Kansas, within the Kansas City Metropolitan Area, the affordable multifamily community consists of 41 townhome-style buildings comprised of 161 apartment units.

Led by Dustin Swartz, Managing Director, and Karl Rincavage, Senior Analyst, Walker & Dunlop arranged the loan on behalf of the borrower, Vazza Real Estate Group. The loan was processed using Fannie Mae’s Green Rewards Program, which provides lower pricing and additional loan proceeds to support financing green property improvements.

“This property is a fantastic addition to our multifamily portfolio,” said Stephen F. Vazza, President of Vazza Real Estate Group. “We really like the Kansas City market and are actively looking for more multifamily opportunities in the area.” Vazza Real Estate Group is a Boston-based real estate firm with a portfolio that is primarily focused on major secondary markets with strong economic drivers. “We are seeing better cap rates and overall returns in these markets,” Vazza went on to say. “With interest rates at a historic low, we have been able to acquire over 1,200 apartments this year in excellent markets including Kansas, Kentucky, and Alabama.”

Mr. Swartz added, “This deal demonstrates Fannie Mae’s ability to provide very attractive financing terms for affordable housing properties, which support Fannie Mae’s mission-driven housing goals. Working with Fannie Mae, we provided an excellent debt execution for the borrower to fund 80 percent of their purchase price on a 12-year fixed rate loan with a four-year interest-only period. This is Walker & Dunlop’s first transaction with Vazza Real Estate Group, and we look forward to working with them on many future debt opportunities.”

The property was built in three phases between 1994 and 1998 with Low Income Housing Tax Credit (LIHTC) equity. A Land Use Restrictive Agreement (LURA) is tied to each phase of the property, with 130 apartments, representing 81 percent of the total units, restricted to households earning 60 percent or less of area median income.

Walker & Dunlop is one of the largest multifamily lenders and ranks within the top five affordable lenders in the United States. For more information about Walker & Dunlop’s commitment to corporate responsibility, including our Diversity & Inclusion, affordable housing, and Green Financing initiatives, download our 2020 ESG summary.

About Walker & Dunlop

Walker & Dunlop (NYSE: WD), headquartered in Bethesda, Maryland, is one of the largest commercial real estate finance companies in the United States. The company provides a comprehensive range of capital solutions for all commercial real estate asset classes, as well as investment sales brokerage services to owners of multifamily properties. Walker & Dunlop is included on the S&P SmallCap 600 Index and was ranked as one of FORTUNE Magazine’s Fastest Growing Companies in 2014, 2017, and 2018. Walker & Dunlop’s 900+ professionals in 40 offices across the nation have an unyielding commitment to client satisfaction.

View original content to download multimedia:http://www.prnewswire.com/news-releases/walker–dunlop-provides-financing-for-affordable-housing-development-in-kansas-city-301185248.html

SOURCE Walker & Dunlop, Inc.

NASHVILLE, Tenn., Dec. 3, 2020 /PRNewswire/ — Kirkland’s, Inc. (NASDAQ: KIRK) today announced financial results for its third fiscal quarter ended October 31, 2020 and the authorization of a new share repurchase plan.

“The momentum we established late last year has continued through the third quarter with positive comparable sales in both the store and e-commerce channels exceeding our expectations, significant year-over-year margin improvement and permanent cost reductions driving earnings growth and cash generation,” noted Woody Woodward, Chief Executive Officer. “While home furnishing is currently receiving the benefit of the reallocation of customer spending, there is much within this transformation of Kirkland’s that is a direct result of our own actions and investments. We have elevated the merchandise assortment with improved quality and design while maintaining our value proposition, improved our customer experience both in store and online and adapted our financial and operating infrastructure to maximize profitability.  We are pleased with the impact these changes have had on our performance and are even more encouraged by the fact that the benefits have become very evident at these early stages of our evolution.”

Mr. Woodward added, “The increased demand driven by our e-commerce channel and the strong performance in both our harvest and Christmas season merchandise more than offset the 51 fewer stores in the base from a year ago. The late October re-launch of our loyalty program has already added hundreds of thousands of new members in a few weeks’ time, and we are pleased with the response to Black Friday and Cyber Monday. Similar to others in our sector, we continued to experience a shift to online during the month of November with Black Friday shopping spread out over a longer period. We believe we have established a good start to the fourth quarter by growing profitability with year-over-year margin gains and a solid comparable sales improvement, particularly in e-commerce.”

Strategic Priorities and Financial Goals

Kirkland’s key strategic initiatives include:

• Accelerating product development to reinforce quality and relevancy as we continue the transformation of the Kirkland’s brand into a specialty retailer where customers are able to furnish their entire home on a budget;
• Improving omni-channel via website enhancements, more focused marketing spend, an expanded online assortment, and an in-store experience that is aligned with our omni-channel capabilities;
• Improving the customer experience with a re-launch of our loyalty program, extended credit options and broadened delivery options; and
• Utilizing our leaner infrastructure to be more nimble in our response to changes in consumer preference and buying behaviors.

Kirkland’s annual financial goals for the next two to three years include:

• Improving comparable sales performance, driven by e-commerce growth, merchandising, brick-and-mortar store productivity and closure of underperforming stores. We expect e-commerce to continue to grow as a percent of our total business, but also intend to focus on improving the contribution of our remaining store base, which is an integral part of our omni-channel strategy and supports improved profitability of our e-commerce sales.
• Stabilizing gross margin by continuing with our current discipline of limited promotional offers, expanding direct sourcing, improving supply chain efficiency and reducing occupancy costs. With improved merchandise quality and to support a better customer experience, we will continue to move towards more targeted promotions. Direct sourcing is expected to increase from approximately 20% of purchases in 2020 to 40% to 50% over the next two to three years. With these product margin improvements, continued efficiencies in our supply chain and lower occupancy costs, our goal is to improve our annual gross profit margin to a low to mid-30% range over the next two to three years.
• Improving profitability by leveraging the leaner infrastructure with comparable sales growth. We believe our ideal store count should be in the range of 300 to 350 stores. With nearly one-third of our store leases up for renewal within the next 12 months, we believe there will be additional opportunities for more favorable rent terms. With approximately $45 million in annualized operating expenses eliminated from the business, we have a goal of reaching annual EBITDA as a percent of sales in the high-single-digit range and annual operating income in the mid-single-digit range within two to three years.
• Maintaining adequate liquidity and generating free cash flow while continuing to invest in key strategic initiatives of the business and returning excess cash to our shareholders. Our goal is to continue to build cash throughout fiscal 2020 and end the year with no debt. Within our two to three-year timeframe, we also expect to generate increasing free cash flow.

The key strategic initiatives and financial goals are based on current information as of December 3, 2020, and are dependent on, among other things, consumer preferences, economic conditions and our own successful execution of these initiatives. The information on which these initiatives and financial goals is based is subject to change, and investors are cautioned that the Company may update the initiatives and goals, or any portion thereof, at any time for any reason.

Board Authorizes $20 Million Share Repurchase Plan

Kirkland’s also announced today that its Board of Directors has authorized a new share repurchase plan providing for the purchase in the aggregate of $20 million of the Company’s outstanding common stock. Repurchases of shares will be made in accordance with applicable securities laws and may be made from time to time in the open market or by negotiated transactions. The amount and timing of repurchases will be based on a variety of factors, including stock price, regulatory limitations and other market and economic factors. The share repurchase plan does not require the Company to repurchase any specific number of shares, and the Company may terminate the repurchase plan at any time.

Investor Conference Call and Web Simulcast

Kirkland’s will hold its earnings call for the third quarter later today at 9:00 a.m. ET. Participating on the call will be Steve Woodward, Chief Executive Officer and Nicole Strain, Chief Financial Officer. The number to call for the interactive teleconference is (412) 542-4163. A replay of the conference call will be available through Thursday, December 10, 2020 by dialing (412) 317-0088 and entering the confirmation number 10149811.

A live webcast of Kirkland’s quarterly conference call will be available online on the Company’s Investor Relations Page on December 3, 2020, beginning at 9:00 a.m. ET. The online replay will follow shortly after the call and continue for one year.

About Kirkland’s, Inc.

Kirkland’s, Inc. is a specialty retailer of home décor in the United States, currently operating 381 stores in 35 states as well as an e-commerce website, www.kirklands.com. The Company’s stores present a curated selection of distinctive merchandise, including holiday décor, furniture, wall décor, art, textiles, mirrors, fragrances, lamps and other home decorating items. The Company’s stores offer an extensive assortment of holiday merchandise during seasonal periods. The Company provides its customers an engaging shopping experience characterized by casual, comfortable merchandise with a southern feel and a modern flair at a discernible value. This combination of quality and stylish merchandise, value pricing and a stimulating online and store experience has led the Company to develop a loyal customer base. More information can be found at www.kirklands.com.

Forward-Looking Statements 

Except for historical information contained herein, the statements in this release, including all statements related to future initiatives, financial goals and expectations regarding any future period, are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are subject to the finalization of the Company’s quarterly financial and accounting procedures. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Kirkland’s actual results to differ materially from forecasted results. Those risks and uncertainties include, among other things, risks associated with the Company’s progress and anticipated progress towards its long-term objective and the success of its plans in response to the novel coronavirus (“COVID-19”), the spread of COVID-19 and its impact on the Company’s revenues and supply chain, risks associated with COVID-19 and the governments responses to it, the impact of store closures in 2020, the effectiveness of the Company’s marketing campaigns, risks related to changes in U.S. policy related to imported merchandise, particularly with regard to the impact of tariffs on goods imported from China and strategies undertaken to mitigate such impact, the Company’s ability to retain its senior management team, continued volatility in the price of the Company’s common stock, the competitive environment in the home décor industry in general and in Kirkland’s specific market areas, inflation, fluctuations in cost and availability of products, interruptions in supply chain and distribution systems, including our e-commerce systems and channels, the ability to control employment and other operating costs, availability of suitable retail locations and other growth opportunities, disruptions in information technology systems including the potential for security breaches of Kirkland’s or its customers’ information, seasonal fluctuations in consumer spending, and economic conditions in general. Those and other risks are more fully described in Kirkland’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K filed on April 10, 2020 and subsequent reports. Forward-looking statements included in this release are made as of the date of this release. Any changes in assumptions or factors on which such statements are based could produce materially different results. Kirkland’s disclaims any obligation to update any such factors or to publicly announce results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.

Non-GAAP Financial Measures

To supplement our unaudited consolidated condensed financial statements presented in accordance with generally accepted accounting principles (“GAAP”), this earnings release and the related earnings conference call contain certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted operating income (loss), adjusted net income (loss) and adjusted diluted income (loss) per share. These measures are not in accordance with, and are not intended as alternatives to, GAAP. The Company uses these non-GAAP financial measures internally in analyzing our financial results and believes that they provide useful information to analysts and investors, as a supplement to GAAP measures, in evaluating our operational performance.

The Company defines EBITDA as net income or loss before interest, provision for income tax, and depreciation and amortization, adjusted EBITDA as EBITDA with non-GAAP adjustments and adjusted operating income (loss) as operating income (loss) with non-GAAP adjustments. The Company defines adjusted net income (loss) and adjusted diluted income (loss) per share by adjusting the applicable GAAP measure for non-GAAP adjustments.

Non-GAAP measures are intended to provide additional information only and do not have any standard meanings prescribed by GAAP. Use of these terms may differ from similar measures reported by other companies. Each non-GAAP measure has its limitations as an analytical tool, and you should not consider them in isolation or as a substitute for analysis of the Company’s results as reported under GAAP.

The following table shows a reconciliation of operating income (loss) to EBITDA, adjusted EBITDA and adjusted operating income (loss) for the 13 weeks and 39 weeks ended October 31, 2020 and November 2, 2019 and a reconciliation of net income (loss) and diluted income (loss) per share to adjusted net income (loss) and adjusted diluted income (loss) per share for the 13 weeks and 39 weeks ended October 31, 2020 and November 2, 2019:

Contact:

Kirkland’s
Nicole Strain
(615) 872-4800

Investor Relations
[email protected]
(615) 872-4898

View original content to download multimedia:http://www.prnewswire.com/news-releases/kirklands-reports-third-quarter-2020-results-301185128.html

SOURCE Kirkland’s, Inc.

NEW YORK, Dec. 3, 2020 /PRNewswire/ — Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) (“Actinium”) today highlighted that four abstracts detailing the Company’s clinical trials for Iomab-B and Actimab-A will be presented at the 62^nd American Society of Hematology (ASH) Annual Meeting, which is being held virtually December 5-8, 2020.

Sandesh Seth, Actinium’s Chairman and CEO said “ASH is always a productive meeting for Actinium and we are excited that this year we have our largest presence ever with three oral presentations and a poster presentation.  We are thrilled to have the opportunity to highlight the promising data from the pivotal phase 3 SIERRA trial for Iomab-B and our two Actimab-A combination trials with CLAG-M and venetoclax.  Notably, we head into ASH with a series of milestones expected for year-end and next year in addition to a strong cash position of $48 million at the end of the third quarter that will allow us to meet our development objectives well into 2022.  We are also excited by recent developments in R&D and our recent senior hires that will enable us to succeed in achieving our near-term milestones and long-term vision for Actinium.”

Mark Berger, Actinium’s Chief Medical officer, said, “We are pleased to present updated data from our Iomab-B pivotal Phase 3 SIERRA trial and Actimab-A combination trials this weekend at ASH.  We are excited by the progress we have made across our pipeline and the strong potential our targeted radiotherapy agents have for improving the care of patients with relapsed or refractory AML.  The data we will present at this year’s meeting is a reflection of the hard work done by our Actinium team and by our clinical sites to demonstrate the promise of our Antibody Radiation Conjugates.  We would like to thank everyone for their contributions to this effort and we look forward to sharing the detailed presentations and updated data at this important meeting.”

Iomab-B Oral Presentations Details:

Actimab-A CLAG-M Oral Presentation Details:

Actimab-A Venetoclax Poster Presentation Details:

About Actinium Pharmaceuticals, Inc. (NYSE: ATNM)

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation.  Actinium’s lead application for our ARCs is targeted conditioning, which is intended to selectively deplete a patient’s disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities.  With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently.  Our lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning.  The SIERRA trial is over seventy-five percent enrolled and positive single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings.  More information on this Phase 3 clinical trial can be found at sierratrial.com. I-131 apamistamab will also be studied as a targeted conditioning agent in a Phase 1 study with a CD19 CAR T-cell Therapy and Phase 1/2 anti-HIV stem cell gene therapy with UC Davis.  In addition, we are developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.  Ongoing combination trials include our CD33 alpha ARC, Actimab-A, in combination with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax.  Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform.  This is where our intellectual property portfolio of over 100 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster our pipeline for strategic purposes.  Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc. Website: https://www.actiniumpharma.com/

Forward-Looking Statements for Actinium Pharmaceuticals, Inc. 

This press release may contain projections or other “forward-looking statements” within the meaning of the “safe-harbor” provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium’s products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium’s filings with the Securities and Exchange Commission (the “SEC”), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Contacts:

Investors:
Clayton Robertson
Actinium Pharmaceuticals, Inc.
[email protected]

Hans Vitzthum

LifeSci Advisors, LLC
[email protected] 
(617) 430-7578

View original content to download multimedia:http://www.prnewswire.com/news-releases/actinium-highlights-clinical-data-to-be-presented-at-the-upcoming-62nd-american-society-of-hematology-annual-meeting-301185566.html

SOURCE Actinium Pharmaceuticals, Inc.

SAN DIEGO, Dec. 3, 2020 /PRNewswire/ — Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the U.S. Department of Veterans Affairs (VA) has awarded the Company a contract for the purchase of Phexxi® (lactic acid, citric acid and potassium bitartrate) for a five-year period beginning December 15, 2020.

Saundra Pelletier, CEO of Evofem Biosciences, said, “This award is an important milestone in our ongoing effort to create the broadest access to Phexxi for all patients.  We have achieved coverage for 55% of commercial lives in the U.S., including nearly 8 million lives at zero copay,  and are very pleased to expand into government programs. We look forward to providing Phexxi to the women who are a part of this program, which includes VA, Tricare, Department of Defense, Coast Guard and Indian Health Services and under which approximately 12 million lives will have access to Phexxi.” 

This award was recently listed on the U.S. government’s SAM website. 

About the Department of Veterans Affairs Federal Supply Schedule (VA FSS)
Under delegated authority by GSA, the VA manages multiple award contracts for medical equipment, supply, pharmaceutical, and service Schedule programs. With over $14 billion in sales, the VA FSS Service supports the healthcare requirements of the VA and other federal government agencies by providing Federal customers with access to over 1 million state-of-the-art commercial products and services.

About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company’s first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, ‘EVOGUARD,’ for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. For more information, please visit www.evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Forward-Looking Statements
This press release includes “forward-looking statements,” within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended; and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to the U.S. Department of Veterans Affairs contract award. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could impair the value of Evofem Biosciences’ assets and business, are disclosed in Evofem’s SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 12, 2020, its Current Report on Form 8-K filed with the SEC on June 2, 2020, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 filed with the SEC on November 9, 2020. All forward-looking statements are expressly qualified in their entirety by such factors. Evofem does not undertake any duty to update any forward-looking statement except as required by law.

Investor Relations Contact

Amy Raskopf

Evofem Biosciences, Inc.
[email protected] 
Mobile: (917) 673-5775

Media Contact

Ellen Thomas

Evofem Biosciences, Inc.
[email protected]
Mobile: (718) 490-3248

View original content to download multimedia:http://www.prnewswire.com/news-releases/the-us-department-of-veterans-affairs-awards-contract-to-evofem-biosciences-for-phexxi-301185490.html

SOURCE Evofem Biosciences, Inc.

HOUSTON, Dec. 3, 2020 /PRNewswire/ — Landcadia Holdings II, Inc. (“Landcadia II” or the “Company”) (Nasdaq: LCA) announced today that it has scheduled the special meeting in lieu of the 2020 annual meeting of its stockholders (the “Special Meeting”) for December 18, 2020 at 10:30 a.m., Eastern time, to, among other things, approve the proposed business combination (the “Business Combination”) between Landcadia II and Golden Nugget Online Gaming, LLC (“GNOG”). The Company also announced that it has filed its definitive proxy statement for the Special Meeting and has commenced mailing the definitive proxy statement to its stockholders of record as of October 29, 2020, the record date for the Special Meeting (the “Record Date”). The closing of the Business Combination is subject to approval by Landcadia II’s stockholders and the satisfaction of other customary closing conditions and is expected to close as soon as practicable following the Special Meeting.

Your vote is important no matter how many shares you own. You are encouraged to submit your vote as soon as possible.
 If you hold your shares in “street name,” meaning that your shares are held at an account at a brokerage firm, bank or other similar agent, you may vote prior to the Special Meeting by using your voting control number and instructions provided to you by your brokerage firm, bank or other similar agent. Please contact your brokerage firm, bank or other similar agent to ensure your shares are voted. If you are a stockholder of record, you may vote prior to the Special Meeting by signing, dating, and mailing your proxy card in the return envelope provided with your proxy material.

If you have any questions or need assistance voting your shares, please contact Morrow Sodali LLC, our proxy solicitor, by calling (800) 662-5200, or banks and brokers can call collect at (203) 658-9400, or by emailing [email protected].

About GNOG
Golden Nugget Online Gaming, Inc. is a leading online gaming company that is owned by a company wholly owned by Tilman J. Fertitta. It is considered a market leader by its peers and was first to bring Live Dealer and Live Casino Floor to the United States online gaming market. GNOG was the recipient of 15 eGaming Review North America Awards, including the coveted “Operator of the Year” award in 2017, 2018, 2019 and 2020.

About Landcadia Holdings II, Inc.
Landcadia Holdings II, Inc. is a company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses that is co-sponsored by Fertitta Entertainment, Inc. and Jefferies Financial Group Inc.

Important Information About the Business Combination and Where to Find It

Landcadia II has filed a definitive proxy statement with the Securities and Exchange Commission (the “SEC”) for the Special Meeting to be held in connection with its Business Combination with GNOG.  Landcadia II’s stockholders and other interested persons are advised to read the definitive proxy statement and documents incorporated by reference therein filed in connection with the Business Combination, as these materials contain important information about GNOG, Landcadia II and the Business Combination.  The definitive proxy statement and other relevant materials for the Special Meeting were mailed to stockholders of Landcadia II as of the Record Date.  Landcadia II’s stockholders may also obtain copies of the definitive proxy statement and other documents filed with the SEC that will be incorporated by reference therein, without charge, at the SEC’s web site at www.sec.gov, or by directing a request to: Landcadia Holdings II, Inc., 1510 West Loop South, Houston, Texas 77027, Attention: General Counsel, (713) 850-1010. 

Participants in the Solicitation

Landcadia II and its directors and executive officers may be deemed participants in the solicitation of proxies from Landcadia II’s stockholders with respect to the Business Combination.  A list of the names of those directors and executive officers and a description of their interests in Landcadia II is contained in Landcadia II’s definitive proxy statement, which was filed with the SEC and is available free of charge at the SEC’s web site at www.sec.gov, or by directing a request Landcadia Holdings II, Inc., 1510 West Loop South, Houston, Texas 77027, Attention: General Counsel, (713) 850-1010.  

GNOG and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of Landcadia II in connection with the Business Combination.  A list of the names of such directors and executive officers and information regarding their interests in the Business Combination is included in the proxy statement for the Business Combination.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.  Landcadia II’s and GNOG’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward looking statements as predictions of future events.  Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements.  These forward-looking statements include, without limitation, Landcadia II’s and GNOG’s expectations with respect to future performance and anticipated financial impacts of the Business Combination, the satisfaction of the closing conditions to the Business Combination and the timing of the completion of the Business Combination.  These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.  Most of these factors are outside Landcadia II’s and GNOG’s control and are difficult to predict.  Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the purchase agreement for the Business Combination (the “Purchase Agreement”) or could otherwise cause the Business Combination to fail to close, (2) the outcome of any legal proceedings that may be instituted against Landcadia II and GNOG following the announcement of the Purchase Agreement and the transactions contemplated therein; (3) the inability to complete the Business Combination, including due to failure to obtain approval of the stockholders of Landcadia II or satisfy other conditions to closing in the Purchase Agreement; (4) the impact of COVID-19 on GNOG’s business and/or the ability of the parties to complete the Business Combination; (5) the inability to obtain or maintain the listing of Landcadia II’s shares of common stock on The Nasdaq Stock Market following the Business Combination; (6) the risk that the Business Combination disrupts current plans and operations as a result of the announcement and consummation of the Business Combination; (7) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of GNOG to grow and manage growth profitably and retain its key employees; (8) costs related to the Business Combination; (9) changes in applicable laws or regulations; (10) the possibility that GNOG or Landcadia II may be adversely affected by other economic, business, and/or competitive factors; and (11) other risks and uncertainties indicated from time to time in the proxy statement relating to the Business Combination, including those under “Risk Factors” therein, and in Landcadia II’s other filings with the SEC.  The foregoing list of factors is not exclusive.   Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made.  Neither GNOG nor Landcadia II undertakes or accepts any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. 

No Offer or Solicitation

This press release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Business Combination.  This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.  No offering of securities shall be made except by means of a prospectus meeting the requirements of section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

View original content:http://www.prnewswire.com/news-releases/landcadia-ii-announces-special-meeting-date-to-approve-proposed-business-combination-with-gnog-301185535.html

SOURCE Landcadia Holdings II, Inc.

THE WOODLANDS, Texas, Dec. 3, 2020 /PRNewswire/ — Newpark Resources, Inc. (NYSE: NR) (“Newpark” or the “Company”) announced today that it received written notification from the New York Stock Exchange (the “NYSE”) that it has regained compliance with the NYSE continued listing standards.

As previously disclosed, on November 4, 2020, the Company received formal notice from the NYSE that it was not in compliance with the NYSE’s continued listing standards as a result of the average closing price of the Company’s common stock being less than $1.00 per share during a consecutive 30 trading-day period.

The Company regained compliance after its closing share price on November 30, 2020 and its average closing share price for the 30 trading-day period ending November 30, 2020 both exceeded $1.00. Accordingly, the Company has resumed compliance under the NYSE continued listing standard and the “.BC” indicator following the Company’s symbol “NR” will be removed by the NYSE.

Newpark Resources, Inc. is a geographically diversified supplier providing products, as well as rentals and services to a variety of industries, including oil and gas exploration, electrical transmission & distribution, pipeline, renewable energy, petrochemical, and construction industries. For more information, visit our website at www.newpark.com.

Contacts: Gregg Piontek

Senior Vice President & Chief Financial Officer

Newpark Resources, Inc.


[email protected]


281-362-6800

View original content:http://www.prnewswire.com/news-releases/newpark-resources-regains-compliance-with-nyse-listing-standards-301185521.html

SOURCE Newpark Resources, Inc.